Collaboration Initial Public Offering Medical 
Cooley M&A
JANUARY 25, 2023
But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions. Let’s dig in.
Cooley M&A
JANUARY 23, 2024
Collaborate or buy?’ question remains key Buyers in the life sciences industry continue to face the decision of whether to acquire a company or enter into a collaboration deal, which is influenced by the potential benefits of the partnership, the risks of only partial control, the ability to align on upfront valuation and antitrust risk.
Expert insights. Personalized for you.
40 
Let's personalize your content